BPMC News and Press, Blueprint Medicines Corporation From 12/09/19

Merck's $2.7B bid for ArQule is yet another example of the Big Biopharma's high regard for oral kinase inhibitors for treating cancer. ArQule's lead drug is ARQ 531, an oral inhibitor of Bruton's tyrosine kinase (BTK). More news on: Pfizer Inc., Eli Lilly and Company, AbbVie Inc., Health...

CAMBRIDGE, Mass. , Dec. 8, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced initial data from the Phase 2 PIONEER clinical trial of avapritin...

Approval from the U.S. Food and Drug Administration is a big step in the life of a biotech company. It's the difference between theory and reality, between hopes and money in the bank. FDA approval not only means that a company can start selling its drugs, but also that the company might have a ...

CAMBRIDGE, Mass. , Nov. 14, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy,  today announced that Jeff Albers , Blueprint Medicines' Chief ...

Blueprint suffers GIST setbacks NDA changes Blueprint Medicines ( BPMC ) recently announced the FDA will split Avapritinib New Drug Application into separate submissions for PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST, setting the company back a quarter. In order to prioritize ...

CAMBRIDGE, Mass. , Nov. 6, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that an abstract for the ongoing Phase 2 PIONEER clinical trial ...

Blueprint Medicines  (NASDAQ: BPMC ): Q3 GAAP EPS of -$1.93 beats by $0.26 . More news on: Blueprint Medicines Corporation, Earnings news and commentary, Healthcare stocks news, Read more ...

CAMBRIDGE, Mass. , Nov. 5, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, is hosting its first R&D Day in New York City today.  D...

Don’t Believe? Then don’t bother reading. Readers familiar with our work may want to skip to the Comparing Details heading below. Blueprint Medicines Corporation ( BPMC ), in a temporary 9% price drawdown, provides an opportunity for prompt recovery capital gain. This...

CAMBRIDGE, Mass. , Oct. 29, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that it will host a Research and Development (R&a...